Therapeutic efficacy of intravitreal bevacizumab on posterior uveitis complicated by neovascularization
Open Access
- 17 April 2009
- journal article
- case report
- Published by Wiley in Acta Ophthalmologica
- Vol. 87 (3) , 349-352
- https://doi.org/10.1111/j.1755-3768.2008.01208.x
Abstract
Purpose: To evaluate the therapeutic effect of intravitreal bevacizumab in patients with uveitis‐associated choroidal/retinal neovascularization. Methods: Two female patients (40 years, 15 years) with posterior uveitis, (one presumed ocular sarcoidosis, one lupus) were evaluated for neovascularization of the posterior segment. Both patients were given a single dose of 1.25 mg intravitreal bevacizumab. Results: Significant anatomical and functional recovery was evident in both patients within a few weeks. Conclusion: In selected uveitic patients, bevacizumab may be an option for managing neovascularization.Keywords
This publication has 7 references indexed in Scilit:
- Vascular endothelial growth factor in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalitiesArchivum Immunologiae et Therapiae Experimentalis, 2007
- The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwideBritish Journal of Ophthalmology, 2006
- Clinical implications for Vascular Endothelial Growth Factor in the lung: friend or foe?Respiratory Research, 2006
- Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremitiesClinical Rheumatology, 2004
- Incidence and prevalence of uveitis in Northern California The Northern California Epidemiology of Uveitis StudyOphthalmology, 2004
- Serum vascular endothelial growth factor as a possible prognostic indicator in sarcoidosis.Lung, 2003
- Pulmonary vascular involvement in sarcoidosis: A report of 40 autopsy casesHuman Pathology, 1992